Enterprise Value
55.6M
Cash
67.61M
Avg Qtr Burn
-21.42M
Short % of Float
10.84%
Insider Ownership
0.79%
Institutional Own.
22.69%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral Bivalent Norovirus Vaccine Details Infectious disease, Norovirus | Phase 2 Data readout | |
Monovalent Norovirus Vaccine Details Infectious disease, Norovirus | Phase 2 Update | |
VXA-A1.1 Details Influenza | Phase 2 Update | |
Oral Bivalent Norovirus Vaccine Details Infectious disease, Norovirus | Phase 1 Data readout | |
VXA-CoV2-1 Details COVID-19 | Phase 1 Update |